Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shay Menascu

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Brain Communications|January 9, 2025
Machine learning-based prediction of disease progression in primary progressive multiple sclerosisMichael Gurevich, Rina Zilkha-Falb, Jia Sherman, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of Neurology|March 2, 2022
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimodAnat Achiron, Mathilda Mandel, Michael Gurevich, et al.
Multiple Sclerosis and Related Disorders|March 18, 2023
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumabAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
The Journal of Pediatrics|March 25, 2011
Neurologic presentation in children with ataxia-telangiectasia: is small head circumference a hallmark of the disease?Andreea Nissenkorn, Yonit Banet Levi, Daphna Vilozni, et al.
Brain : a Journal of Neurology|March 10, 2018
RSRC1 mutation affects intellect and behaviour through aberrant splicing and transcription, downregulating IGFBP3Yonatan Perez, Shay Menascu, Idan Cohen, et al.
BMC Neurology|April 18, 2015
A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohortAlon Kalron, Dalia Nitzani, David Magalashvili, et al.
Journal of Neuroimmunology|October 16, 2021
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional studyAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Plos One|August 13, 2013
Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional studyAnat Achiron, Joab Chapman, David Magalashvili, et al.
Seizure|January 23, 2016
CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experienceMichal Tzadok, Shimrit Uliel-Siboni, Ilan Linder, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Brain Communications|January 9, 2025
Machine learning-based prediction of disease progression in primary progressive multiple sclerosisMichael Gurevich, Rina Zilkha-Falb, Jia Sherman, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of Neurology|March 2, 2022
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimodAnat Achiron, Mathilda Mandel, Michael Gurevich, et al.
Multiple Sclerosis and Related Disorders|March 18, 2023
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumabAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
The Journal of Pediatrics|March 25, 2011
Neurologic presentation in children with ataxia-telangiectasia: is small head circumference a hallmark of the disease?Andreea Nissenkorn, Yonit Banet Levi, Daphna Vilozni, et al.
Brain : a Journal of Neurology|March 10, 2018
RSRC1 mutation affects intellect and behaviour through aberrant splicing and transcription, downregulating IGFBP3Yonatan Perez, Shay Menascu, Idan Cohen, et al.
BMC Neurology|April 18, 2015
A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohortAlon Kalron, Dalia Nitzani, David Magalashvili, et al.
Journal of Neuroimmunology|October 16, 2021
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional studyAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Plos One|August 13, 2013
Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional studyAnat Achiron, Joab Chapman, David Magalashvili, et al.
Seizure|January 23, 2016
CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experienceMichal Tzadok, Shimrit Uliel-Siboni, Ilan Linder, et al.
Pageof 8